

Anna M Eiring

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/733894/publications.pdf>

Version: 2024-02-01

70
papers

3,270
citations

304602

22
h-index

149623

56
g-index

72
all docs

72
docs citations

72
times ranked

5035
citing authors

#	ARTICLE	IF	CITATIONS
1	miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts. <i>Cell</i> , 2010, 140, 652-665.	13.5	514
2	FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosomeâ€“positive acute lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2007, 117, 2408-2421.	3.9	308
3	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	7.7	292
4	Pushing the limits of targeted therapy in chronic myeloid leukaemia. <i>Nature Reviews Cancer</i> , 2012, 12, 513-526.	12.8	260
5	Sp1/NFÎ±B/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia. <i>Cancer Cell</i> , 2010, 17, 333-347.	7.7	235
6	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 4144-4157.	3.9	192
7	BCR-ABL1 compound mutations in tyrosine kinase inhibitorâ€“resistant CML: frequency and clonal relationships. <i>Blood</i> , 2013, 121, 489-498.	0.6	187
8	Zebrafish screen identifies novel compound with selective toxicity against leukemia. <i>Blood</i> , 2012, 119, 5621-5631.	0.6	138
9	Age-related mutations and chronic myelomonocytic leukemia. <i>Leukemia</i> , 2016, 30, 906-913.	3.3	119
10	Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. <i>Leukemia</i> , 2015, 29, 586-597.	3.3	111
11	Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. <i>Leukemia</i> , 2012, 26, 1140-1143.	3.3	97
12	High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2â€“dependent suppression of C/EBPÎ±-driven myeloid differentiation. <i>Blood</i> , 2007, 110, 994-1003.	0.6	91
13	A role for FOXO1 in BCRâ€“ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. <i>Leukemia</i> , 2016, 30, 1493-1501.	3.3	57
14	miR-155 promotes FLT3-ITDâ€“induced myeloproliferative disease through inhibition of the interferon response. <i>Blood</i> , 2017, 129, 3074-3086.	0.6	57
15	Lenalidomide-mediated enhanced translation of C/EBPÎ±-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. <i>Blood</i> , 2013, 121, 159-169.	0.6	56
16	Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. <i>Blood</i> , 2008, 111, 816-828.	0.6	44
17	shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. <i>Blood</i> , 2015, 125, 1772-1781.	0.6	41
18	Î²-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. <i>Leukemia</i> , 2015, 29, 2328-2337.	3.3	37

#	ARTICLE	IF	CITATIONS
19	Advances in the treatment of chronic myeloid leukemia. <i>BMC Medicine</i> , 2011, 9, 99.	2.3	36
20	Targeting LFA-1 and CD154 Suppresses the In Vivo Activation and Development of Cytolytic (CD4-Independent) CD8+T Cells. <i>Journal of Immunology</i> , 2005, 175, 7855-7866.	0.4	31
21	Nuclearâ€“Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. <i>Clinical Cancer Research</i> , 2019, 25, 2323-2335.	3.2	24
22	Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. <i>Genome Biology</i> , 2014, 15, 461.	3.8	23
23	Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)â€“Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. <i>ChemMedChem</i> , 2016, 11, 850-861.	1.6	23
24	KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2013, 73, 5775-5786.	0.4	22
25	Evidence for Tissue-Directed Immune Responses: Analysis of CD4- and CD8-Dependent Alloimmunity. <i>Transplantation</i> , 2004, 78, 1125-1133.	0.5	20
26	Activation and Maturation of Alloreactive CD4-Independent, CD8+Cytolytic T Cells. <i>American Journal of Transplantation</i> , 2006, 6, 2268-2281.	2.6	20
27	Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B. <i>Oncogene</i> , 2021, 40, 2697-2710.	2.6	20
28	CD4+ T-Cell???Dependent Immune Damage of Liver Parenchymal Cells Is Mediated by Alloantibody. <i>Transplantation</i> , 2005, 80, 514-521.	0.5	18
29	Direct Contact With Bone Marrow Stromal Cells Protects CML Progenitors From Imatinib Through Cytoplasmic Stabilization Of Î²-Catenin. <i>Blood</i> , 2013, 122, 3982-3982.	0.6	17
30	Critical Role for CD8+ T Cells in Allograft Acceptance Induced by DST and CD40/CD154 Costimulatory Blockade. <i>American Journal of Transplantation</i> , 2004, 4, 1061-1070.	2.6	14
31	Alloreactive (CD4-Independent) CD8+ T Cells Jeopardize Long-Term Survival of Intrahepatic Islet Allografts. <i>American Journal of Transplantation</i> , 2008, 8, 1113-1128.	2.6	14
32	A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia. <i>Cells</i> , 2021, 10, 2833.	1.8	14
33	What challenges remain in chronic myeloid leukemia research?. <i>Haematologica</i> , 2013, 98, 1168-1172.	1.7	13
34	26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy. <i>Cells</i> , 2021, 10, 2390.	1.8	13
35	Energy metabolism and drug response in myeloid leukaemic stem cells. <i>British Journal of Haematology</i> , 2019, 186, 524-537.	1.2	12
36	Ethnic and border differences on blood cancer presentation and outcomes: A Texas populationâ€“based study. <i>Cancer</i> , 2021, 127, 1068-1079.	2.0	11

#	ARTICLE	IF	CITATIONS
37	A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. <i>Leukemia</i> , 2015, 29, 1668-1675.	3.3	10
38	Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. <i>Experimental Hematology</i> , 2015, 43, 537-545.e11.	0.2	10
39	Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. <i>Leukemia</i> , 2020, 34, 2981-2991.	3.3	8
40	The new role of microRNAs in cancer. <i>Future Oncology</i> , 2010, 6, 1203-1206.	1.1	7
41	MS4A3: A New Player in Leukemic Stem Cell Survival in Chronic Myeloid Leukemia. <i>Blood</i> , 2016, 128, 934-934.	0.6	7
42	MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β -chain cytokine receptor endocytosis. <i>Blood</i> , 2022, 139, 761-778.	0.6	7
43	Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics. <i>Vaccines</i> , 2022, 10, 816.	2.1	7
44	Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells. <i>Leukemia</i> , 2020, 34, 1679-1683.	3.3	6
45	Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. <i>Leukemia</i> , 2016, 30, 2275-2279.	3.3	4
46	Selective Inhibition of Nuclear Cytoplasmic Transport As a New Treatment Paradigm in Myelofibrosis. <i>Blood</i> , 2016, 128, 636-636.	0.6	4
47	Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 5055.	1.7	4
48	Blood cancer health disparities in the United States Hispanic population. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a005967.	0.5	2
49	MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 14-14.	0.6	2
50	STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2012, 120, 31-31.	0.6	2
51	Stroma-Based Activation of pSTAT3Y705 Confers Resistance to FLT3 Inhibitors in FLT3 ITD-Positive AML. <i>Blood</i> , 2016, 128, 34-34.	0.6	2
52	Femoral Heads from Total Hip Arthroplasty as a Source of Adult Hematopoietic Cells. <i>Acta Haematologica</i> , 2021, 144, 458-464.	0.7	1
53	Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib. <i>Blood</i> , 2011, 118, 2481-2481.	0.6	1
54	An Unbiased shRNA Library Screen Identifies Nucleocytoplasmic Transport As a Potential Target For Treatment Of Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2707-2707.	0.6	1

#	ARTICLE	IF	CITATIONS
55	NF- κ B-Dependent Activation of the Proteasome Components, PSMD1 and PSMD3, As a Mechanism of Resistance to Imatinib. <i>Blood</i> , 2019, 134, 2923-2923.	0.6	1
56	Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.. <i>Blood</i> , 2009, 114, 855-855.	0.6	0
57	Frequency and Clonality of BCR-ABL Compound Mutations in Chronic Myeloid Leukemia,. <i>Blood</i> , 2011, 118, 3744-3744.	0.6	0
58	Intrinsic and Extrinsic Survival Signals Converge on STAT3 As a Critical Mediator of BCR-ABL-Independent Tyrosine Kinase Inhibitor Resistance,. <i>Blood</i> , 2011, 118, 3742-3742.	0.6	0
59	Suppression of CML Progenitor but Not Stem Cells Requires Simultaneous Inhibition of KIT and BCR-ABL1.. <i>Blood</i> , 2012, 120, 2778-2778.	0.6	0
60	Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia.. <i>Blood</i> , 2012, 120, 2445-2445.	0.6	0
61	BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 854-854.	0.6	0
62	Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival. <i>Blood</i> , 2014, 124, 4637-4637.	0.6	0
63	Limited Efficacy of BMS-911543 in a Murine Model of JAK2V617F Myeloproliferative Neoplasm. <i>Blood</i> , 2014, 124, 5572-5572.	0.6	0
64	The Tumor Suppressors, MS4A3 and G0S2, Are Downregulated in CML Cells with BCR-ABL1 Kinase-Independent Resistance. <i>Blood</i> , 2014, 124, 1786-1786.	0.6	0
65	Design, Optimization, and Pre-Clinical Evaluation of Direct, Mechanism-Based STAT3 Inhibitors for Treating Myeloid Disorders. <i>Blood</i> , 2014, 124, 4816-4816.	0.6	0
66	Autocrine TNF- α Signaling in Hematopoietic Stem Cells Promotes Myeloproliferative Disease Progression through Activation of TNFR2. <i>Blood</i> , 2014, 124, 1888-1888.	0.6	0
67	Transition of Chronic Myeloid Leukemia to Chronic Myelomonocytic Leukemia As a Tool to Observe Development of Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2015, 126, 5223-5223.	0.6	0
68	Combining Dasatinib and AC220 Reduces Stroma-Based pSTAT5Y694 in FLT3-ITD+ AML and Overcomes FLT3 TKI Resistance. <i>Blood</i> , 2018, 132, 2641-2641.	0.6	0
69	Retrospective Study of Incidence and Survival for Patients with Hematologic Malignancies Residing at the U.S./Mexico Border. <i>Blood</i> , 2019, 134, 4782-4782.	0.6	0
70	A Role for Lipid Metabolism in Tyrosine Kinase Inhibitor (TKI) Resistance of Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2021, 138, 2542-2542.	0.6	0